anti-HBsAg monoclonal antibody (ClearB Therapeutics/Doherty Institute)

N/A

Report date: 2025/06/11 10:17:29

Base Information

Drug Nameanti-HBsAg monoclonal antibody (ClearB Therapeutics/Doherty Institute)
Drug Alias Name4G2+VH3+VL2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHBsAg modulators
TargetsHepatitis B Surface Antigens
Therapy Area/IndicationsHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCopyright The Peter Doherty Institute For Infection And Immunity
China Registration ClassN/A

Develop Information

Active CompaniesClearB Therapeutics IncCopyright The Peter Doherty Institute For Infection And Immunity
Inactive CompaniesN/A
Active IndicationsHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A